A new treatment to enhance the effectiveness of chemotherapy and radiation for glioblastoma patients
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
This study is testing a new drug called onalespib to see if it can help adults with glioblastoma when used alongside regular chemotherapy and radiation, aiming to find the safest dose and improve treatment results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10890045 on NIH RePORTER |
What this research studies
This research investigates a novel drug called onalespib, which targets a specific protein involved in cancer cell survival, to improve treatment outcomes for adults with glioblastoma. The study aims to determine the highest safe dose of onalespib when combined with standard chemotherapy and radiation therapy. By using patient-derived cell lines and animal models, researchers are exploring how this combination can overcome resistance to existing treatments and potentially lead to better tumor control. Patients participating in this trial will be closely monitored for side effects and treatment responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are undergoing or have undergone standard chemotherapy and radiation treatment.
Not a fit: Patients with glioblastoma who are not eligible for chemotherapy or radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and quality of life for patients with glioblastoma by enhancing the effectiveness of current therapies.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting heat shock proteins in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Puduvalli, Vinay K — University of Tx Md Anderson Can Ctr
- Study coordinator: Puduvalli, Vinay K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.